{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:53:41Z","timestamp":1784919221419,"version":"3.55.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000142","name":"The Arthritis Society","doi-asserted-by":"crossref","award":["YIO-13-07"],"award-info":[{"award-number":["YIO-13-07"]}],"id":[{"id":"10.13039\/501100000142","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Canadian Institutes of Health Research Operating Grant: Analyses of Existing Canadian Cohorts and Databases","award":["AO1-151540"],"award-info":[{"award-number":["AO1-151540"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine the association between exposure to biologics in pregnant women with inflammatory systemic diseases and maternal and neonatal outcomes through a meta-analysis of findings from studies identified in a systematic review.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a systematic review of Medline, Embase, and Cochrane Database of Systematic Reviews to identify observational studies assessing the perinatal impacts of biologic in women with inflammatory systemic disease. Findings were meta-analysed across included studies with random-effects models. Crude risk estimates and, where possible, adjusted risk estimates were pooled to determine the impact on results when confounding is addressed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 24 studies were included in the meta-analysis. Meta-analyses of crude risk estimates resulted in pooled odds ratios (OR) for the association of biologic use during pregnancy and the following respective outcomes: congenital anomalies (1.30, 95% CI: 1.02, 1.67), preterm birth (OR 1.61, 95% CI: 1.37, 1.89), and low birth weight (OR 1.68, 95% CI: 1.21, 2.31). However, in pooled analyses of adjusted risk estimates we observed that the association between biologics use during pregnancy in disease-matched exposed and unexposed pregnant women was no longer statistically significant for congenital anomalies (adjusted OR 1.18, 95% CI: 0.88, 1.57).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Pooled results from studies reporting adjusted risk estimates showed no increased risk of congenital anomalies associated with biologics use, suggesting that increased rates of adverse outcomes may be due to disease activity itself or other confounders.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa064","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T20:09:34Z","timestamp":1580846974000},"page":"1808-1817","source":"Crossref","is-referenced-by-count":41,"title":["Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies"],"prefix":"10.1093","volume":"59","author":[{"given":"Nicole W","family":"Tsao","sequence":"first","affiliation":[{"name":"University of British Columbia Faculty of Pharmaceutical SciencesVancouver, BC, Canada"},{"name":"Collaboration for Outcomes Research and Evaluation, Vancouver, BC, Canada"},{"name":"Arthritis Research Canada, Richmond, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevena","family":"Rebic","sequence":"additional","affiliation":[{"name":"University of British Columbia Faculty of Pharmaceutical SciencesVancouver, BC, Canada"},{"name":"Collaboration for Outcomes Research and Evaluation, Vancouver, BC, Canada"},{"name":"Arthritis Research Canada, Richmond, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry D","family":"Lynd","sequence":"additional","affiliation":[{"name":"Collaboration for Outcomes Research and Evaluation, Vancouver, BC, Canada"},{"name":"Centre for Health Evaluation & Outcomes Sciences, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2205-2683","authenticated-orcid":false,"given":"Mary A","family":"De Vera","sequence":"additional","affiliation":[{"name":"University of British Columbia Faculty of Pharmaceutical SciencesVancouver, BC, Canada"},{"name":"Collaboration for Outcomes Research and Evaluation, Vancouver, BC, Canada"},{"name":"Arthritis Research Canada, Richmond, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"2020072516474804900_keaa064-B1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/clpt.2011.278","article-title":"Biologics-based therapy for the treatment of rheumatoid arthritis","volume":"91","author":"Scott","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2020072516474804900_keaa064-B2","doi-asserted-by":"crossref","first-page":"S720","DOI":"10.1067\/mai.2003.146","article-title":"Immunomodulation and immunotherapy: drugs, cytokines, cytokine receptors, and antibodies","volume":"111(2 Suppl","author":"Nelson","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"2020072516474804900_keaa064-B3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"McInnes","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"2020072516474804900_keaa064-B4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cyto.2017.04.012","article-title":"Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines","volume":"98","author":"Kim","year":"2017","journal-title":"Cytokine"},{"key":"2020072516474804900_keaa064-B5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2020072516474804900_keaa064-B6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2020072516474804900_keaa064-B7","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1126\/science.283.5406.1277","article-title":"A gender gap in autoimmunity","volume":"283","author":"Whitacre","year":"1999","journal-title":"Science"},{"key":"2020072516474804900_keaa064-B8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/art.21663","article-title":"Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis","volume":"54","author":"Chakravarty","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2020072516474804900_keaa064-B9","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1186\/1472-6874-4-S1-S18","article-title":"The impact of arthritis on Canadian women","volume":"4(Suppl 1","author":"Badley","year":"2004","journal-title":"BMC Womens Health"},{"key":"2020072516474804900_keaa064-B10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"2020072516474804900_keaa064-B11","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/oxfordjournals.aje.a009735","article-title":"Epidemiology of Crohn\u2019s disease and ulcerative colitis in a central Canadian province: a population-based study","volume":"149","author":"Bernstein","year":"1999","journal-title":"Am J Epidemiol"},{"key":"2020072516474804900_keaa064-B12","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.bpobgyn.2015.03.003","article-title":"Autoimmune connective tissue diseases","volume":"29","author":"\u00d8stensen","year":"2015","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2020072516474804900_keaa064-B13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cgh.2010.02.014","article-title":"Crohn\u2019s disease is a risk factor for preterm birth","volume":"8","author":"Stephansson","year":"2010","journal-title":"Clin Gastroenterol"},{"key":"2020072516474804900_keaa064-B14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/acr.22516","article-title":"Proceedings from the American College of Rheumatology reproductive health summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases","volume":"67","author":"Kavanaugh","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2020072516474804900_keaa064-B15","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/acr.23434","article-title":"Patterns of biologics utilization and discontinuation before and during pregnancy in women with autoimmune diseases: a population-based cohort study","volume":"70","author":"Tsao","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2020072516474804900_keaa064-B16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaut.2016.11.004","article-title":"Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-\u03b1 use in females with immune mediated diseases; a systematic review and meta-analysis","volume":"76","author":"Komaki","year":"2017","journal-title":"J Autoimmun"},{"key":"2020072516474804900_keaa064-B17","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2020072516474804900_keaa064-B18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.reprotox.2013.11.004","article-title":"Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study","volume":"43","author":"Diav-Citrin","year":"2014","journal-title":"Reprod Toxicol"},{"key":"2020072516474804900_keaa064-B19","first-page":"262","article-title":"Biologic therapy in pregnant women with inflammatory bowel disease","volume":"27","author":"Martinez","year":"2014","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2020072516474804900_keaa064-B20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2015.08.039","article-title":"Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy","volume":"14","author":"Br\u00f6ms","year":"2016","journal-title":"Clin Gastroenterol"},{"key":"2020072516474804900_keaa064-B21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2016-209322","article-title":"Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020072516474804900_keaa064-B22","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/pds.4261","article-title":"Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use","volume":"26","author":"Carman","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2020072516474804900_keaa064-B23","first-page":"218","article-title":"Birth outcomes following pregnancy exposure to adalimumab: the OTIS autoimmune diseases in pregnancy project","volume":"26(Suppl 2","author":"Chambers","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2020072516474804900_keaa064-B24","first-page":"869","article-title":"Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study","volume":"77","author":"Tsao","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020072516474804900_keaa064-B25","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/ibd.21583","article-title":"Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy","volume":"17","author":"Schnitzler","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2020072516474804900_keaa064-B26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/apt.12833","article-title":"Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease","volume":"40","author":"Seirafi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2020072516474804900_keaa064-B27","doi-asserted-by":"crossref","first-page":"S574","DOI":"10.1016\/S0016-5085(17)32079-6","article-title":"Evaluation of safety and efficacy of antitnfa treatment among 11275 pregnancies occurring in 8726 women with in inflammatory bowel diseases. Study on the French national health insurance database","volume":"152 (5 Suppl 1","author":"Luu","year":"2017","journal-title":"Gastroenterology"},{"key":"2020072516474804900_keaa064-B28","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ajg.2017.501","article-title":"Long-term safety of in utero exposure to anti-TNF\u03b1 Drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study","volume":"113","author":"Chaparro","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2020072516474804900_keaa064-B29","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2010.140822","article-title":"Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register","volume":"70","author":"Verstappen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2020072516474804900_keaa064-B30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.5217\/ir.2016.14.2.139","article-title":"Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and\/or thiopurine therapy: a multicenter study from Japan","volume":"14","author":"Komoto","year":"2016","journal-title":"Intest Res"},{"key":"2020072516474804900_keaa064-B31","first-page":"30","article-title":"Tnf inhibitor treatment during pregnancy and risk of preterm birth","volume":"27 (Suppl 2","author":"Br\u00f6ms","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2020072516474804900_keaa064-B32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/ajg.2012.430","article-title":"Safety of thiopurines and anti-TNF-\u03b1 drugs during pregnancy in patients with inflammatory bowel disease","volume":"108","author":"Casanova","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2020072516474804900_keaa064-B33","doi-asserted-by":"crossref","first-page":"j895","DOI":"10.1136\/bmj.j895","article-title":"Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study","volume":"356","author":"Desai","year":"2017","journal-title":"BMJ"},{"key":"2020072516474804900_keaa064-B34","first-page":"236","article-title":"No increase in serious or opportunistic infections in infants prenatally exposed to biologics","volume":"27 (Suppl 2","author":"Chambers","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2020072516474804900_keaa064-B35","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/art.40536","article-title":"Serious infections in rheumatoid arthritis offspring exposed to tumor necrosis factor inhibitors","volume":"70","author":"Vinet","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2020072516474804900_keaa064-B36","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.autrev.2014.12.011","article-title":"State of the art: reproduction and pregnancy in rheumatic diseases","volume":"14","author":"\u00d8stensen","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2020072516474804900_keaa064-B37","doi-asserted-by":"crossref","first-page":"A437","DOI":"10.1016\/j.autrev.2011.11.013","article-title":"Interaction of pregnancy and autoimmune rheumatic disease","volume":"11","author":"\u00d8stensen","year":"2012","journal-title":"Autoimmun Rev"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/8\/1808\/33532611\/keaa064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/8\/1808\/33532611\/keaa064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T20:49:45Z","timestamp":1595710185000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/8\/1808\/5771282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,3,2]]},"published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa064","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,3,2]]}}}